Management Team

Hanna Kirk

MSc, VP of Product Development

Hanna is a process orientated quality expert with broad understanding of pharmaceutical drug development. She holds Master’s degree in Analytical and Pharmaceutical Science and has Lean Six Sigma Green Belt in Project Management. Hanna has worked more than ten years in pharmaceutical industry at varied roles from subject matter expert to managerial roles. She has been regularly trained in GMP and ISO 9001 quality management systems and she has gained experience on regulatory procedures with FDA, EMA and FIMEA. Hanna has been a contributing member of a team achieving successful marketing authorization approval for NDA/MAA while working at GSK. Hanna will strengthen the CMC team to meet the regulatory targets aligned with TILT strategy.

Akseli Hemminki

MD, PhD, eMBA, Founder & CEO and Member of the Board of Directors

Aino Kalervo

MSc, MS, Chief Operating Officer

John Goldfinch

MBA, CRM, US Clinical Lead & CEO - TILT Biotherapeutics LLC

Suvi Sorsa

PhD, VP of Clinical Affairs

Tuija Keinonen

PhD, Prof, Chair of the Board of Directors, Chief Regulatory Officer

Kari Varkila

MD, PhD, MBA, Chief Medical Officer

Chad Hellmann

MBA, Capital Strategy - Advisor

Víctor Cervera-Carrascón

PhD, VP of Business Development

Riikka Havunen

PhD, VP of Operations